These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 340032)

  • 1. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
    Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
    Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
    Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
    Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.
    Al-Sarraf M; Thigpen T; Groppe CW; Haut A; Padilla F
    Cancer Treat Rep; 1978 Jul; 62(7):1101-3. PubMed ID: 356973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
    Weick JK; Jones SE; Ryan DH
    Cancer Treat Rep; 1983 May; 67(5):489-92. PubMed ID: 6687839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
    Rossof AH; Coltman CA; Jones SE; Talley RW
    Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of piperazinedione in patients with advanced cancer.
    Currie V; Woodcock T; Tan C; Krakoff I; Young C
    Cancer Treat Rep; 1979 Jan; 63(1):73-6. PubMed ID: 369694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
    Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
    Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
    Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of pyrazofurin, alone and in combination with trifluorothymidine, in non-Hodgkin's lymphoma.
    Warrell RP; Currie V; Kempin S; Young C
    Cancer Treat Rep; 1979 Aug; 63(8):1423-5. PubMed ID: 113097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
    Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
    Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
    O'Connell MJ; Begg CB; Silverstein MN; Glick JH; Oken MM
    Cancer Treat Rep; 1980; 64(12):1355-8. PubMed ID: 7008938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
    Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
    Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
    Palmer RL; Samal BA; Vaughn CB; Tranum BL
    Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
    Presant CA; Bartolucci AA; Ungaro P; Oldham R
    Cancer Treat Rep; 1979 Aug; 63(8):1367-9. PubMed ID: 476710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.